Keiichiro Kushiro | Director of Research
Mucommune

Keiichiro Kushiro, Director of Research, Mucommune

I. My Story in a Nutshell
Since my birth, I have lived around the globe (Tanzania, Singapore, Thailand, Chile, USA, etc.), got my higher educational degrees in USA, and later joined the University of Tokyo as faculty in the Department of Bioengineering. My past achievements include my original research projects on controlling cellular behaviors such as cancer metastasis through geometrical features of microstructured biomaterials that resulted in publications in prominent scientific journals. I have also extensively worked on various areas of bioengineering including microstructured biodevices to isolate and analyze cancer cells, fluorescence/radiation probes for bioimaging and drug delivery to tumors, and creation of polymer-coated artificial lungs. I recently made a transition from academia to industry, and now serve as the Senior Director of Research in a US biotech startup called Mucommune in North Carolina, where I spearhead many projects related to implantable biodevices to prevent sexually transmitted diseases and bacterial infections, and non-hormonal contraception.

II. Education
California Institute of Technology     (2004~2010)
Ph.D. in Biochemistry and Molecular Biophysics

III. Professional Experience
- Senior Director of Research (2021~), Director of Research (2020~2021) @ Mucommune, LLC.
- Project Lecturer/Associate Professor (2019~2020) @Dept Bioengineering, University of Tokyo

IV. Selected Publications
1. Afzali Z, Matsushita T, Kogure A, Masuda T, Azuma T, Kushiro K, Kasama T, Miyake R, Takai M. (2022). ACS Applied Materials & Interfaces. 14:2605-2617.
2. Zhao T, Asawa K, Masuda T, Honda A, Kushiro K, Cabral H, Takai M. (2021). Journal of Colloid and Interface Science. 601:825-832.
3. Yaginuma T, Kushiro K, Takai M. (2020). Scientific Reports. 10:6110.
4. Olofsson K, Kushiro K, Takai M, M Wiklund, et al. (2018). Lab on a Chip. 18:2466-2476.
5. Kushiro K, Yaginuma T, Ryo A, Takai M (2017). Scientific Reports. 7:4244.
6. Kamata H, Kushiro K, Takai M, Chung U, Sakai T (2016). Angewandte Chemie International Edition (Communication). 55(32): 9282-9286.
7. Kushiro K, Lee C-H, Takai M (2016). Biomaterials Science. 4(6):989-997.
8. Kushiro K, Sakai T, Takai M (2015). Langmuir. 31(37):10215-10222.
9. Cho J, Kushiro K, Teramura Y, Takai M (2014). Biomacromolecules. 15(6): 2012-2018.
10. Kushiro K, Asthagiri AR (2012). Langmuir. 28(9):4357-4362.
11. Kushiro K, Chang S, Asthagiri AR (2010). Advanced Materials. 22: 4516-4519.

Appearances:



Festival of Biologics Day 2 @ 14:50

Next-Generation Multimeric Human Contraceptive Antibody and Vaginal Delivery Platforms

There are currently limited options available for safe and effective non-hormonal contraceptives or methods that block sexually transmitted diseases (STDs). Direct vaginal delivery of monoclonal antibodies (mAb) represents a promising approach towards both goals. In particular, we have been engineering a next-generation, branching multimeric mAb that can efficiently agglutinate and trap sperm in physiological mucus conditions. In addition, due to the diverse lifestyle needs and preferences of women, there is strong market demand for diverse contraceptive formats, ranging from intrauterine devices (IUD) to intravaginal ring (IVR) to implants, patches, injectables, and oral pills. We have been developing both a novel capsule-IVR platform for a long-lasting contraceptive option, as well as fast-dissolving antibody tablets (FDAT) for those who may prefer rapid, on-demand interventions. In sheep studies, vaginally inserted mAb-FDATs achieved uniform distribution in different parts of the vagina within minutes, while fully maintaining virus-neutralization or contraceptive activities. Similarly, our mAb-IVRs enable sustained release of active contraceptive or anti-STD antibodies for over 22 days in animal studies, a period that covers the fertility window in most women. Overall, our results underscore Mucommune’s capsule-IVR and FDAT as promising non-hormonal contraceptives and/or prophylaxes against STDs, capable of delivering biologic interventions to reinforce female reproductive health.

last published: 19/Mar/25 20:05 GMT

back to speakers